International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 2 , Pages 391-395 , 1 February 2008

Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity

  • Howard Safran, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • Corresponding Author InformationReprint requests to: Howard Safran, M.D., Department of Medicine, The Miriam Hospital, 164 Summit Ave., Providence, RI 02906. Tel: (401) 793-7151; Fax: (401) 793-4049
    • ,
  • Mohan Suntharalingam, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
    • ,
  • Thomas Dipetrillo, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Thomas Ng, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • L. Austin Doyle, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • University of Maryland Cancer Center, Baltimore, MD
    • ,
  • Mark Krasna, M.D.

      Affiliations

    • Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
    • ,
  • Angela Plette, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Devon Evans, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Harold Wanebo, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Paul Akerman, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Jeremy Spector, M.D.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Nancy Kennedy, R.N., C.C.R.A.

      Affiliations

    • Brown University Oncology Group, Providence, RI
    • ,
  • Teresa Kennedy, R.N., C.C.R.A.

      Affiliations

    • Brown University Oncology Group, Providence, RI

Received 25 May 2007 ,Revised 3 July 2007 ,Accepted 4 July 2007.

References 

  1. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598
  2. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174
  3. Ilson DH. Cancer of the gastroesophageal junction: current therapy options. Curr Treat Options Oncol. 2006;7:410–423
  4. Ng T, Dipetrillo T, Purviance J, et al. Multi-modality treatment of esophageal cancer: A review of the current status and future directions. Curr Oncol Rep. 2006;8:174–182
  5. Mendelsohn J, Baird A, Fan Z, et al. Growth factors and their receptors in epithelial malignancies. In:  Mendelsohn J,  Howley PM,  Israel MA,  Liotta LA editor. The molecular basis of cancer. Philadelphia, PA: W.B. Saunders Company; 2001;p. 137–144
  6. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17:259–269
  7. Ozawa S, Ueda M, Ando N, et al. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinoma. Cancer. 1989;63:2169–2173
  8. Makuda H, Toi M, Hirai T, et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer. 1991;68:142–148
  9. Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous carcinoma to chemoradiotherapy. Cancer. 1994;74:1693–1698
  10. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemotherapy. Clin Ca Res. 2003;9:6461–6468
  11. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995;95:1897–1905
  12. Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004;59(Suppl):27–38
  13. Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004;58:991–1002
  14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma for the head and neck. N Engl J Med. 2006;354:567–578
  15. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined modality paradigm. J Clin Oncol. 2006;24:1072–1078
  16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  17. Saltz L, Meropol NJ, Loehrer PJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  18. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest. 2001;1:1–7
  19. Safran H, DiPetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;67:405–409
  20. Brenner B, Ilson DH, Minsky BD. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004;22:45–52
  21. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251–260
  22. Ajani JA, Ilson D, Dougherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natal Cancer Inst. 1994;86:1086–1091
  23. Choy H, Rodriguez FF, Koester S, et al. Investigation of Taxol as a potential radiation sensitizer. Cancer. 1993;71:3774–3778
  24. Lineman J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natal Cancer Inst. 1994;86:441–446
  25. Edelstein DJ, Rice TW, Rebecca LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18:2032–2039
  26. Khushalani N, Leichamn CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844–2850
  27. Urba S, Hyman J, Intone M, et al. Pre-operative chemoradiation with cisplatin (CDDP), 5-fluorouracil (5FU), and paclitaxel (Tax), followed by surgery and adjuvant chemotherapy, for loco-regional esophageal carcinoma. [abstract] Proc Am Soc Clin Oncol. 2004;22:14s
  28. Burmeister BH, Smothers BM, Gaskin V, et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomized controlled phase III trial. Lancet Oncol. 2005;6:659–668

 Presented in part at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), November 5–9, 2006, Philadelphia, PA.

 Dr. Safran and Dr. Mohan report receiving grant support and honoraria from Bristol-Myers in the amount of less than $100,000. No other potential conflict of interest relevant to this article was reported.

PII: S0360-3016(07)03668-1

doi: 10.1016/j.ijrobp.2007.07.2325

International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 2 , Pages 391-395 , 1 February 2008

Article Tools